UK Life Sciences
Webinar 2020

Shirley Lam

셜리 람

Ms. Shirley Lam is responsible for developing business and partnerships with advanced therapy companies and research institutes in Asia Pacific, as well as building the business strategy for this territory. Prior to joining the Catapult, Shirley spent five years developing innovation partnerships between the UK and Asia to facilitate joint R&D, knowledge transfer and trade in the health and technology sectors. She also worked on research projects in various labs in the UK and Hong Kong. Her expertise spans across research, business/partnership development, project management, technology transfer and marketing.
Shirley obtained her MSc in Infection and Immunity from University College London and BSc in Medical Biochemistry from King’s College London in the UK.

Dr Andrew Roddam

앤드류 로댐

- Vice President Data Strategy & Design, Data & Computational Science (GSK) 2018 – 2020
- Vice President & Global Head Epidemiology (GSK) 2013 – 2018
- Director Observational Research & International Head, Center for Observational Research, (Amgen Ltd) 2009 - 2013
- Co-investigator: MRC: The Million Women Study. £4.9m 2007 - 2012
- Principal Investigator: HSE: The relationship between shift work and disease. £529,474 2008 - 2011
- Honorary Research Fellow in Cancer Epidemiology (University of Oxford) 2006
- Chartered Statistician, Royal Statistical Society 2003

Dr Fiona Reddington

피오나 레딩턴

- 1993 – 1997 : BSc (Pharmacology) - University College Dublin
- 1997 – 2000 : PhD (Neurophysiology) - Kings College London
- Worked at National Cancer Research Institute Informatics Initiative from August 2003 – August 2006. Part of the team to win the inaugural Times Higher Research Project of the Year award
- Seconded to ADD project, a major new research initiative that was announced as part of the Life Sciences Sector Deal 2 in 2019 as the interim Chief Operating Officer

Prof Tim Hubbard

팀 허버드

- 2018- Associate Director of the London site of the new UK national institute, Health Data Research UK (HDRUK)
- 2013- Professor of Bioinformatics and Head of the Department of Medical & Molecular Genetics at King's College London
- 2013- Head of Genome Analysis at Genomics England, the company set up by the Department of Health to execute the 100,000 genomes project, which aims to mainstream the use of whole genome sequence analysis for treatment in the UK National Health Service (NHS)
- 1997-2013 Head of Human Genome Analysis at the Wellcome Trust Sanger Institute; 2007-13 Head of Informatics; where he was one of the organisers of the sequencing of the human genome
- 2007-13 led the GENCODE project to annotate the structure of all human genes
- 1999 co-founded the Ensembl project to analysis, organise and provide access to the human genome
- 1994 co-founded the Structural Classification of Proteins Database (SCOP)

Chris Molloy

크리스 몰로이

- Founding CEO of the Medicines Discovery Catapult in 2016
- 30-year international board and executive career across a unique range of life sciences R&D disciplines, starting at Glaxo
- Former COO of MerLion Pharmaceuticals, Singapore
- Winner of a Queen’s Award for Enterprise
- Chair of the IP Advisory Committee for the Association of Medical Research Charities, Industry Advisory Board for Manchester’s Biomedical Research Centre & Health Innovation Manchester
- Honorary Chair at the University of Manchester
- Holder of US and EU patents in HIV drug discovery

Noor Shaker

누르 샤커

- BBC 100 Women 2019
- MIT innovators under 35
- Rising Star Award from the Former British Prime Minister
- Ph.D. in Artificial Intelligence
- 50+ publications and 2000+ citations
- Featured in WIRED and Forbes

Dr Julie Brady

줄리 브래디

- 1996 PhD Rowett Research Institute, University of Aberdeen
- PDRA in University of Glasgow for 1 year followed by Rowett Research Institute for 3 years (1996 – 2000)
- Technology Transfer in Universities of Dundee and St Andrews for 3 years (2000 – 2003)
- Life Sciences Manager for Scottish Enterprise for 10 years (2003 – 2013)
- Business Development Lead for Drug Discovery since 2013

Kyu-Jin Park

박규진

- 2018 - Present: Director, Head of Translational Research and In Vivo Pharmacology at CKD Research Institute, Chong Kun Dang Pharmaceutical Corp.
- 2010 - 2018: Sr. Research Scientist/ Project Leader, Cancer Cell Growth & Epigenetics, Oncology, Eli Lilly and Company, Indianapolis, Indiana
- 2006 - 2010: Research Scientist/ Project Leader, Cancer Cell Growth & Epigenetics, Oncology, Eli Lilly and Company, Indianapolis, Indiana
- 2003 - 2006: Postdoctoral Research Fellow, Cancer Cell Growth & Translation, Oncology, Eli Lilly and Company, Indianapolis, Indiana
- 2001 - 2003: Postdoctoral Research Fellow, Division of Hematology-Oncology, Department of Medicine, University of Texas Southwestern Medical Center at Dallas, Texas
- 2001: Ph.D. in Microbiology, Kangwon National University, Korea
- 2013: First place in Lilly Oncology Shark Tank: an outstanding display of leadership and command skills

Jennifer Rho

노지혜

- Seoul National University
- Harvard Business School, MBA
- (2006~2010) The Boston Consulting Group, Project Leader
- (2010~2014) LG Electronics / Manager of management strategy
- (2015~2018) Amorepacific Group / Head of Strategy Division
- (2019~Now) Hugel

Simon Smith

사이먼 스미스

Opening Speech

Simon Smith has been British Ambassador to the Republic of Korea since March 2018. He began his career in the Diplomatic Service in 1986, and has also worked at the British Embassies in Kiev, Vienna, Tokyo and Moscow. Simon is from Bristol, and studied German and French at Oxford University.

Harjinder Kang

하진더 캉

Opening Speech

- Harjinder joined the Civil Service following a private sector career of over 30 years within the global pharmaceutical industry, primarily with AstraZeneca PLC, where he held numerous senior roles. He is the Vice Chair of Sandwell & West Birmingham Hospitals NHS Trust and is also serving the Council of the University of Birmingham.
- In 2016 Harjinder founded Abnasia Ltd, an independent consulting firm specialising in providing commercial expertise to the global pharma industry and was engaged by many of the top pharma companies to assist them with their strategic commercial issues.
- Harjinder was offered the opportunity to join the Department for International Trade in 2019 to lead this vitally important area of the economy. The pace of innovation in the UK is staggering, and he is immensely proud to be supporting the healthcare, life sciences and bioeconomy sector. He and his team will do everything in their power to help UK companies and institutions achieve even greater success, both within the UK and abroad.